SpringWorks Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Saqib Islam
- Full Time Employees
- 368
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Washington Boulevard Stamford CT United States of America 06902
- IPO Date
- Sep 13, 2019
- CIK
- 0001773427
- Website
- springworkstx.com
- Similar Companies
- Business
- SpringWorks Therapeutics, Inc. (SWTX) is a biopharmaceutical company focused on developing and commercializing targeted therapies for patients with severe rare diseases and cancers. The company, founded in 2017 and headquartered in Stamford, Connecticut, offers OGSIVEO (nirogacestat), an oral gamma secretase inhibitor approved in the U.S. and EU for adult patients with progressing desmoid tumors who require systemic treatment; GOMEKLI (mirdametinib), an oral MEK1/2 inhibitor approved in the U.S. for adult and pediatric patients aged two years and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) not amenable to complete resection and conditionally approved in the EU; and advances a pipeline including nirogacestat in combination with BCMA-targeting agents for relapsed/refractory multiple myeloma, mirdametinib for low-grade glioma, SW-682 (TEAD inhibitor) for Hippo pathway-driven solid tumors, and SW-3431 (PP2A activator) for rare uterine cancers. In July 2025, Merck KGaA, Darmstadt, Germany completed its $3.4 billion acquisition of SpringWorks, integrating its rare tumor portfolio—including OGSIVEO and GOMEKLI—with Merck's investigational pimicotinib for tenosynovial giant cell tumor (TGCT) to form a dedicated rare tumor business unit and accelerate global commercialization. SpringWorks operates primarily in the U.S. and EU, targeting underserved patient populations in rare oncology and genetically defined cancers through collaborations with entities such as Children's Oncology Group, St. Jude Children’s Research Hospital, and prior industry partners including GSK, Janssen, Pfizer, and Regeneron.
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Immunome: SpringWorks Buyout Informs The Potential Upside Here
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders